Form 4: Jazz Pharma Director's Equity Changes Reported

Jazz Pharmaceuticals plc Director Norbert G. Riedel reported the grant of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Norbert G. Riedel, a Director of Jazz Pharmaceuticals plc (JAZZ), reported changes in his beneficial ownership of ordinary shares.
• On August 7, 2025, Mr. Riedel was granted 3,507 restricted stock units (RSUs) at a price of $0.0 per unit, pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• These RSUs represent a contingent right to receive one ordinary share upon vesting, which is scheduled to occur in full on July 24, 2026, subject to continuous service and other conditions.
• On August 8, 2025, Mr. Riedel disposed of 1,805 ordinary shares at a price of $111.2498 per share.
• This disposition was specifically for the purpose of satisfying tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, Mr. Riedel directly beneficially owns 7,024 ordinary shares.
• Additionally, 10,630 ordinary shares are indirectly beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by Mr. Riedel and his immediate family.

Sentiment

Score: 5

Explanation: The filing reports routine insider equity compensation (grant of RSUs) and a standard tax-related sale, which is a neutral event for company performance or outlook.

Positives

• The grant of 3,507 restricted stock units at no cost represents equity compensation for the Director's service, aligning his interests with shareholders.

Negatives

• The sale of 1,805 shares, while for tax obligations, reduces the Director's direct beneficial ownership of the company's stock.

Future Outlook

The 3,507 restricted stock units granted to Director Norbert G. Riedel are scheduled to vest in full on July 24, 2026, contingent on his continuous service and other conditions.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape for Jazz Pharmaceuticals plc.

Related Party Transactions

• 10,630 ordinary shares are indirectly beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family.

Next Steps

• Vesting of 3,507 restricted stock units on July 24, 2026, subject to conditions.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Director, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Beneficial Ownership